Duavee patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7683051 WYETH PHARMS Crystalline polymorph of bazedoxifene acetate
Mar, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6479535 WYETH PHARMS 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
May, 2024

(7 months from now)

Duavee is owned by Wyeth Pharms.

Duavee contains Bazedoxifene Acetate; Estrogens, Conjugated.

Duavee has a total of 2 drug patents out of which 0 drug patents have expired.

Duavee was authorised for market use on 03 October, 2013.

Duavee is available in tablet;oral dosage forms.

Duavee can be used as prevention of postmenopausal osteoporosis; treatment of moderate to severe vasomotor symptoms associated with menopause.

The generics of Duavee are possible to be released after 10 March, 2027.

Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient

Market Authorisation Date: 03 October, 2013

Treatment: Prevention of postmenopausal osteoporosis; Treatment of moderate to severe vasomotor symptoms associated with menopause


More Information on Dosage

DUAVEE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic